NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
122 trialsNCT06199466 2025-12-08
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT04527900 2025-06-19
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Phase 2 Terminated
NCT04251169 2025-06-03
TATEN
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04856176 2025-01-01
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
Phase 2 Terminated
NCT06752135 2024-12-30
HRCC1
Azienda Policlinico Umberto I
Terminated
NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
NCT03367871 2024-06-18
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Phase 2 Terminated
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02834975 2023-11-07
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Phase 2 Terminated
NCT01041027 2023-10-26
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01303679 2023-09-06
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 3 Terminated
NCT02112552 2023-08-29
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01367301 2023-08-21
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT02530437 2023-07-10
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT01407562 2022-09-28
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT02756013 2022-06-30
Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00358163 2022-04-29
Trial of PTK787/ZK 222584 Plus Paclitaxel
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02824575 2022-04-04
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Montefiore Medical Center
Phase 1 Terminated
NCT03278626 2022-03-28
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NYU Langone Health
Phase 1/2 Terminated
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT03029611 2022-01-14
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
University of Washington
Phase 2 Terminated
NCT00960297 2021-12-06
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00566540 2021-11-26
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00618917 2021-11-12
MnSOD
University of Pittsburgh
Phase 1/2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT00542191 2021-05-26
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Leo W. Jenkins Cancer Center
Phase 2 Terminated
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT00506779 2020-11-18
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT00003086 2020-07-14
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Terminated
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT01548924 2020-04-17
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1 Terminated
NCT01847677 2020-04-01
NOVA
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Terminated
NCT03852979 2020-01-10
NEOCON-F
The Netherlands Cancer Institute
Phase 2 Terminated
NCT02661815 2019-11-08
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02920450 2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2 Terminated